# Stork Therapeutics, Inc. — Form D

Stork Therapeutics, Inc. of SAN FRANCISCO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2025-05-08. The offering totals $2.7M, of which $1.3M was reported sold. Industry: Biotechnology.

## Offering

- Filed: 2025-05-08
- Form: D
- Accession: 0002059988-25-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $2.7M
- Amount sold: $1.3M
- Remaining: $1.4M
- Investors: 3
- Date of first sale: 2025-04-24
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-545504

## Issuer

- Name: Stork Therapeutics, Inc.
- CIK: 0002059988
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2024
- Address: 325 15TH AVENUE, SAN FRANCISCO, CA, 94118
- Phone: (415) 699-7583

## Officers, directors & promoters (4)

| Name | Role | Location |
| --- | --- | --- |
| Gregg Fine | Director | San Francisco, CA |
| Brendan Kennedy | Director | San Francisco, CA |
| Gregg Fine | Executive Officer | San Francisco, CA |
| Gregg Fine | Promoter | San Francisco, CA |

## More

- [CIK 2059988 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2059988&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0002059988-25-000001.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.